Home > Boards > US Listed > Biotechs >

Regen BioPharma Inc. (RGBP)

RGBP RSS Feed
Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, LOVE*PINK, MIKEY501, ronrooster, CMsixfigures, Truenorth2016
Search This Board: 
Last Post: 12/2/2020 2:37:22 PM - Followers: 421 - Board type: Free - Posts Today: 98

Picture

Regen BioPharma 
Followers: 388 Since 10/10/19

 0.000x  Ticker Symbol: RGBP 
Last iBox update 08/09/2020 4PM by CrazyKar123

Barchart


HOT NEWS 
https://www.otcmarkets.com/stock/RGBP/security

Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation


All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html




 
 

Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.


Telephone: (619) 702-1404
Fax: (619) 330-2328




Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia




     
Image result for cbd


 

Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease

 

SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."

 

 







REMEMBER
Always research for yourself BEFORE you buy in the OTC !!!!



RGBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#38745  Sticky Note RGBP listed as a top company/manufacturer for 'Indoleamine LOVE*PINK 12/02/20 11:43:01 AM
#38735  Sticky Note DEC 11th COURT DATE COMING UP....Dont forget this: Truenorth2016 12/02/20 11:25:05 AM
#38732  Sticky Note $RGBP is next $ENZC DRUG COMPANY. MONSTER MOVE COMING. LOVE*PINK 12/02/20 11:21:28 AM
#38056  Sticky Note back down to 2's gotinearly 08/27/20 10:35:07 AM
#37964  Sticky Note Look into filing history of RGBP, delinquent, lawsuit, ronrooster 08/17/20 10:58:45 AM
#38812   I'm watching....where are the company updates? drog68 12/02/20 02:37:22 PM
#38811   DUDE THERE WAS NO COVID AND VIRUS PROBLEMS Truenorth2016 12/02/20 02:36:19 PM
#38810   .0017s HERE IS THIS THE NEXT ENZ*C OR WHAT!!! Truenorth2016 12/02/20 02:35:39 PM
#38809   lol i'm no whale by no means i Chivito 12/02/20 02:34:46 PM
#38808   VERY THIN. PENNYLAND BOUND. LOVE*PINK 12/02/20 02:34:43 PM
#38807   BOOOOOM LOVE*PINK 12/02/20 02:34:17 PM
#38806   They have been at this for a long drog68 12/02/20 02:34:07 PM
#38805   .0017 up sucker got thin koolmc 12/02/20 02:33:44 PM
#38804   no i salp 14'a 15's i dont play Chivito 12/02/20 02:33:35 PM
#38803   When you finally think your bids going to Peepson 12/02/20 02:31:33 PM
#38802   look how thin it got same way how koolmc 12/02/20 02:31:33 PM
#38801   0,0013? harmsen 12/02/20 02:31:21 PM
#38800   .0015 koolmc 12/02/20 02:31:06 PM
#38799   block hits coming in koolmc 12/02/20 02:30:35 PM
#38798   slapping another 10Million eff it lol Chivito 12/02/20 02:30:21 PM
#38797   slapping another 10Million eff it lol Chivito 12/02/20 02:29:54 PM
#38796   Wow - epic DD LOVE*PINK 12/02/20 02:29:30 PM
#38795   https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159866586 Truenorth2016 12/02/20 02:29:04 PM
#38794   On RGBP Website at the bottom of the Truenorth2016 12/02/20 02:28:28 PM
#38793   Yes, Sir. Entering BLUESKY BREAKOUT MODE. LOVE*PINK 12/02/20 02:25:35 PM
#38792   Is there another RGBP share class? joe botts 12/02/20 02:23:20 PM
#38791   OH cool looking forward to it! Thank you. airmikeyy 12/02/20 02:19:07 PM
#38790   Hi guys I'm in! Did anyone else airmikeyy 12/02/20 02:17:13 PM
#38789   1hr 45 Minutes left, still time to close strong!! Truenorth2016 12/02/20 02:14:34 PM
#38788   Would be Great if this did half as joe botts 12/02/20 02:12:03 PM
#38787   It's getting tight next step up! RGBP koha 12/02/20 01:51:21 PM
#38786   Exactly. Churning nicely :-) LOVE*PINK 12/02/20 01:31:15 PM
#38784   Organic run coming here LOVE*PINK 12/02/20 01:25:31 PM
#38783   Anyone trying to get an order filled at 0012? suny66 12/02/20 01:24:35 PM
#38782   Only 3.3 MIL on 0013 Ask...Traders are holding. Truenorth2016 12/02/20 01:06:35 PM
#38781   Second leg up Daytrader1 12/02/20 01:06:21 PM
#38780   Looking good. Thank you. trackkwizzard 12/02/20 01:03:56 PM
#38779   RGBP Current Bid 1052100 BID .0011 X Truenorth2016 12/02/20 12:59:26 PM
#38778   11x12 ron51ron51 12/02/20 12:55:10 PM
#38777   How's the bid aand ask looking. No level trackkwizzard 12/02/20 12:52:47 PM
#38776   finally both tickers rocking at the same time. gotinearly 12/02/20 12:47:43 PM
#38775   RGBP Looking Fantastic!!! Truenorth2016 12/02/20 12:44:56 PM
#38774   Sounds good big guy waterpro42 12/02/20 12:38:15 PM
#38773   Excellent Q7. This is becoming an organic play LOVE*PINK 12/02/20 12:34:32 PM
#38772   People havent seen the prior DD here and Truenorth2016 12/02/20 12:32:51 PM
#38771   Welcome Peeps. just what this play need, reputable traders..... Truenorth2016 12/02/20 12:31:01 PM
#38770   Late to the party but I have a Peepson 12/02/20 12:27:29 PM
#38769   do we have an NEW CEO here??`???????? i Diggie-HH 12/02/20 12:26:04 PM
#38768   WHOOP WHOOP Random31 12/02/20 12:25:10 PM
#38767   Only 2 MIL On The Ask, Traders Know Truenorth2016 12/02/20 12:22:50 PM
#38766   Very thin. Low OS runner. LOVE*PINK 12/02/20 12:20:49 PM
#38765   This one tradenride 12/02/20 12:20:12 PM
#38764   ...im at work but tonight i will take Q7 12/02/20 12:18:14 PM
#38763   We could see 0.0018 - 0.002 today and Daytrader1 12/02/20 12:09:55 PM
#38762   Why are these guys so delinquent with their drog68 12/02/20 12:08:22 PM
PostSubject
Consent Preferences